These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6947720)

  • 41. In vivo localization of anti-osteogenic sarcoma 791T monoclonal antibody in osteogenic sarcoma xenografts.
    Pimm MV; Embleton MJ; Perkins AC; Price MR; Robins RA; Robinson GR; Baldwin RW
    Int J Cancer; 1982 Jul; 30(1):75-85. PubMed ID: 6956558
    [No Abstract]   [Full Text] [Related]  

  • 42. Electro-immortalization of B lymphocytes isolated from stomach carcinoma biopsy material.
    Vollmers HP; von Landenberg P; Dämmrich J; Stulle K; Wozniak E; Ringdörfer C; Müller-Hermelink HK; Herrmann B; Zimmermann U
    Hybridoma; 1993 Apr; 12(2):221-5. PubMed ID: 8314599
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A target for tumour-directed therapy.
    Hynes NE; Groner B
    Nat Med; 1995 Jul; 1(7):631. PubMed ID: 7585140
    [No Abstract]   [Full Text] [Related]  

  • 44. Characteristics of a cell surface antigen defined by an anti-human osteogenic sarcoma monoclonal antibody.
    Price MR; Campbell DG; Robins RA; Baldwin RW
    Eur J Cancer Clin Oncol; 1983 Jan; 19(1):81-90. PubMed ID: 6343092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Immunological characteristics of plasmacytic leukemia].
    Jarczok K; Kubińska E; Jagoda K; Krzemień S; Hołowiecki J
    Pol Tyg Lek; 1984 Sep; 39(36):1205-7. PubMed ID: 6334284
    [No Abstract]   [Full Text] [Related]  

  • 46. Antigenicity and drug susceptibility of human osteogenic sarcoma cells "escaping" a cytotoxic methotrexate-albumin-monoclonal antibody conjugate.
    Embleton MJ; Garnett MC; Jacobs E; Baldwin RW
    Br J Cancer; 1984 May; 49(5):559-65. PubMed ID: 6586198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Monoclonal antibody against a naturally occurring rat mammary carcinoma.
    Gunn B; Embleton MJ; Middle JG; Baldwin RW
    Int J Cancer; 1980 Sep; 26(3):325-30. PubMed ID: 7287210
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Isolation of tumour localizing antibodies by immunosorbents. 3. Isolation of heterologous antibodies against human portio carcinoma and hypernephroma (author's transl)].
    Teichmann B; Vogt R
    Arch Geschwulstforsch; 1974; 43(2):145-56. PubMed ID: 4849017
    [No Abstract]   [Full Text] [Related]  

  • 49. Detection of circulating immune complexes in human osteosarcoma.
    Tsang KY; Singh I; Blakemore WS
    Surg Forum; 1978; 29():560-1. PubMed ID: 401262
    [No Abstract]   [Full Text] [Related]  

  • 50. Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate.
    Embleton MJ; Rowland GF; Simmonds RG; Jacobs E; Marsden CH; Baldwin RW
    Br J Cancer; 1983 Jan; 47(1):43-9. PubMed ID: 6571783
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug/antibody conjugates. In vitro cytotoxicity of a human serum albumin-mediated conjugate of methotrexate with anti-MM46 monoclonal antibody.
    Endo N; Kato Y; Takeda Y; Saito M; Umemoto N; Kishida K; Hara T
    Acta Paediatr Jpn; 1987 Aug; 29(4):566-8. PubMed ID: 3144892
    [No Abstract]   [Full Text] [Related]  

  • 52. [An attempt of determining anti-tumour antibodies in neoplasms of the mammary gland (author's transl)].
    Kovác R; Schmidt P; Kliment M
    Cesk Gynekol; 1975 Feb; 40(1):32-3. PubMed ID: 1131893
    [No Abstract]   [Full Text] [Related]  

  • 53. Interferon-alpha conjugation to human osteogenic sarcoma monoclonal antibody 791T/36.
    Pelham JM; Gray JD; Flannery GR; Pimm MV; Baldwin RW
    Cancer Immunol Immunother; 1983; 15(3):210-6. PubMed ID: 6577942
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Properties of spontaneous rat mammary carcinoma CaM-LEW. II. Karyological characteristics and antigenic properties of CaM-LEW tumour, long term passaged in vivo and in vitro.
    Krenová D; Kren V; Stark O
    Neoplasma; 1969; 16(5):523-30. PubMed ID: 5364147
    [No Abstract]   [Full Text] [Related]  

  • 55. Purification of radioiodinated monoclonal antibodies using a simple 'closed procedure' device.
    Sampson CB; Solanki C
    Nucl Med Commun; 1991 Mar; 12(3):243-7. PubMed ID: 1857585
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Advantage of highly immunoreactive monoclonal antibodies in radioimmunoscintigraphy for tumor detection: (I) New purification system for monoclonal antibodies].
    Yokoyama K
    Kaku Igaku; 1988 Jan; 25(1):49-59. PubMed ID: 3373807
    [No Abstract]   [Full Text] [Related]  

  • 57. Measurement of tumour reactive antibody and antibody conjugate by competition, quantitated by flow cytofluorimetry.
    Robins RA; Laxton RR; Garnett M; Price MR; Baldwin RW
    J Immunol Methods; 1986 Jun; 90(2):165-72. PubMed ID: 2424997
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Reactivity of monoclonal antibodies in cytotoxicity and immunofluorescence tests].
    Koubek K
    Cas Lek Cesk; 1982 Nov; 121(44):1359-63. PubMed ID: 6756637
    [No Abstract]   [Full Text] [Related]  

  • 59. Monoclonal antibodies as enhancers of the host's immunoresponse against the tumour.
    Mellstedt H
    Ann Oncol; 2000; 11 Suppl 3():191-4. PubMed ID: 11079140
    [No Abstract]   [Full Text] [Related]  

  • 60. [Immunologic manifestations in the serum of patients with malignant diseases].
    Konopík J; Chaloupecká P; Kohout P; Jakoubková J; Lintner L
    Cesk Dermatol; 1975 Jun; 50(3):169-73. PubMed ID: 1139664
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.